Shire Plc (LON:SHP) had its stock rating reiterated as ‘Overweight’ in a report released by analysts at Jefferies.
Jefferies today set a target price of 6300 on the company’s stock. According to the analyst this now indicates there is a potential increase of 22.43% from Shire Plc’s current price of 5146.
Over the last twelve months Shire Plc’s stock price has increased by 11.78% from 4603.72 to 5146.
There are currently 682,799,000 shares in issue with a current share value of 5146 giving Shire Plc a market capitalisation of 35.14B GBp .
Shire Plc (LON:SHP) has a 50 day moving average of 5022.47 and a 200 day moving average of 4625.73. The 52 week high for the share price is 5377 while the 52 week low for the stock is 2707.19.
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.